SRT1720 HCl
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
SRT1720是一个可以活化沉默调节蛋白SIRT1的小分子化合物。作为SIRT1的激活剂,SRT1720比resveratrol的作用更强。SRT1720以Sirt1 和PGC-1α依赖的方式影响线粒体呼吸。据报道,SRT1720可以增加胰岛素的敏感性,提高线粒体容量和氧化代谢。在多发性骨髓瘤(MM)细胞中,SRT1720抑制细胞的生长,诱导MM细胞的凋亡,但对正常细胞的细胞活力没有显著影响。SRT1720能够增强bortezomib或dexamethasone的细胞毒性效应。SRT1720的抗MM活性与以下几个方面相关:1)激活caspase-8,caspase-9,caspase-3, 聚(ADP-核糖)聚合酶(PARP);2)增加活性氧;3)诱导磷酸共济失调毛细血管扩张突变/检验点激酶2信号;4)减少血管内皮细胞生长因子诱导的MM细胞的迁移及相关的血管生成;5)抑制核因子κB。
参考文献:
Robin K. Minor, Joseph A. Baur, Ana P. Gomes, Theresa M. Ward, Anna Csiszar, Evi M. Mercken, Kotb Abdelmohsen, Yu-Kyong Shin, Carles Canto, Morten Scheibye-Knudsen, Melissa Krawczyk ,Pablo M. Irusta, Alejandro Mart?´n-Montalvo, Basil P. Hubbard, Yongqing Zhang, Elin Lehrmann, Alexa A. White, Nathan L. Price, William R. Swindell, Kevin J. Pearson, Kevin G. Becker, Vilhelm A. Bohr, Myriam Gorospe, Josephine M. Egan, Mark I. Talan, Johan Auwerx, Christoph H. Westphal, James L. Ellis, Zoltan Ungvari, George P. Vlasuk, Peter J. Elliott, David A. Sinclair, Rafael de Cabo. SRT1720 improves survival and healthspan of obese mice. Scientific Reports. 2011; 1(70): 1038 – 1131.
Kensuke Suzuki, Ryuji Hayashi, Tomomi Ichikawa, Shingo Imanishi, Toru Yamada, Minehiko Inomata, Toshiro Miwa, Shoko Matsui, Isao Usui, Masaharu Urakaze, Yuji Matsuya, Hirofumi Ogawa, Hiroaki Sakurai, Ikuo Saiki, Kazuyuki Tobe. SRT1720, a SIRT1 activator, promotes tumor cell migration, and lung metastasis of breast cancer in mice. Oncology reports. 2012; 27: 1726 -1732.
Dharminder Chauhan, Madhavi Bandi, Ajita V. Singh, Arghya Ray, Noopur Raje, Paul Richardson and Kenneth C.Anderson. Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells. British Journal of Haematology. 2011; 155: 588–598.
- 1. Jinan Elayyan, Idan Carmon, et al. "Lef1 ablation alleviates cartilage mineralization following posttraumatic osteoarthritis induction." Proc Natl Acad Sci U S A. 2022 May 24;119(21):e2116855119. PMID: 35594394
- 2. Xueyu Hu, Gangning Feng, et al. "The Protective Mechanism of SIRT1 on Cartilage Through Regulation of LEF-1." Research Square. doi.org/10.21203/rs.3.rs-214497/v1.
- 3. Yangyang Li, Lei Wang, et al. "SIRT1 Mediates Neuropathic Pain Induced by Sciatic Nerve Chronic Constrictive Injury in the VTA-NAc Pathway." Pain Res Manag 2020 Aug 18;2020:4245968. PMID: 32922581
- 4. Li Y, Xi Y, et al. "Sirtuin 1 activation alleviates primary biliary cholangitis via the blocking of the NF-κB signaling pathway." Int Immunopharmacol. 2020;83:106386. PMID: 32193100
- 5. Lin Y, Liu J, et al. "FADD Phosphorylation Modulates Blood Glucose Levels by Decreasing the Expression of Insulin-Degrading Enzyme." Mol Cells. 2020;43(4):373-383. PMID: 32191993
- 6. Gao P, Li L, et al. "Activation of Transient Receptor Potential Channel Vanilloid 4 by DPP-4 (Dipeptidyl Peptidase-4) Inhibitor Vildagliptin Protects Against Diabetic Endothelial Dysfunction." Hypertension. 2019 Nov 18:HYPERTENSIONAHA11913778. PMID: 31735085
- 7. Lin Q, Fan C, et al. "RELMα Licenses Macrophages for Damage-Associated Molecular Pattern Activation to Instigate Pulmonary Vascular Remodeling." J Immunol. 2019 Oct 14. pii: ji1900535. PMID: 31611261
- 8. Zurlo G, Piquereau J, et al. "Sirtuin 1 regulates pulmonary artery smooth muscle cell proliferation: role in pulmonary arterial hypertension." J Hypertens. 2018 May;36(5):1164-1177. PMID: 29369849
- 9. Cheng CY, Gutierrez NM, et al. "Host sirtuin 1 regulates mycobacterial immunopathogenesis and represents a therapeutic target against tuberculosis." Sci Immunol. 2017 Mar;2(9). pii: eaaj1789. PMID: 28707004
- 10. Wang, Yi, et al. "Specific turn-on fluorescent probe with aggregation-induced emission characteristics for SIRT1 modulator screening and living-cell imaging." Analytical chemistry (2015). PMID: 25903518
Physical Appearance | A solid |
Storage | Store at -20°C |
M.Wt | 506.02 |
Cas No. | 1001645-58-4 |
Formula | C25H23N7OS·HCl |
Synonyms | SRT-1720,SRT 1720,SRT 1720 Hydrochloride |
Solubility | ≥25.3 mg/mL in DMSO; insoluble in EtOH; ≥15.37 mg/mL in H2O with gentle warming and ultrasonic |
Chemical Name | N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide;hydrochloride |
SDF | Download SDF |
Canonical SMILES | C1CN(CCN1)CC2=CSC3=NC(=CN23)C4=CC=CC=C4NC(=O)C5=NC6=CC=CC=C6N=C5.Cl |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
细胞实验[1]: | |
细胞系 |
MDA-MB-231细胞 |
溶解方法 |
在DMSO中的溶解度>10 mM。为了获得更高的浓度,可以将离心管在37℃加热10分钟和/或在超声波浴中震荡一段时间。原液可以在-20℃以下储存几个月。 |
反应条件 |
|
应用 |
SRT1720是SIRT1的激活剂。与对照相比,SRT1720增加约30%的VEGF浓度,表明SRT1720可能促进肿瘤的血管生成。 |
动物实验[1]: | |
动物模型 |
注射4T1细胞的BALB/c小鼠(5周龄,雌性) |
剂量 |
在肿瘤植入前第二天,SRT1720以100 mg/kg的剂量给药,5次/周,在第4、8、12、16和20天测量肿瘤大小。在第21天时,将原发性肿瘤除去,称重后-20?C冷冻。在第28天时处死小鼠,Bouin's溶液处理24小时用于肺部气管内固定。 |
应用 |
SRT1720不能显著影响原发性肿瘤的大小和重量,但显著增加约150%的肺转移。 |
注意事项 |
请测试所有化合物在室内的溶解度,实际溶解度和理论值可能略有不同。这是由实验系统的误差引起的,属于正常现象。 |
References: [1] Suzuki K, Hayashi R, Ichikawa T, et al. SRT1720, a SIRT1 activator, promotes tumor cell migration, and lung metastasis of breast cancer in mice. Oncology reports, 2012, 27(6): 1726-1732. |
描述 | SRT1720是一种选择性的SIRT1激活剂,EC50值为0.16 μM,比对SIRT2和SIRT3作用强230倍。 | |||||
靶点 | SIRT1 | |||||
IC50 | 0.16 μM (EC50) |
质量控制和MSDS
- 批次: